Seeking Alpha

Endologix outlook disappoints Wall Street, shares -24%

Endologix (ELGX -23.9%) shares plummet after the medical device maker reports mixed Q4 results and forecasts FY 2014 revenues below analyst consensus due to slow growth in U.S. device sales.

ELGX sees FY 2014 GAAP EPS loss of $0.44-$0.31 vs. analyst consensus estimate of flat earnings, and revenues of $146M-$152M vs. $161M consensus.

Oppenheimer downgrades shares to Perform from Outperform and lowers its price target to $16 from $20 on ELGX's disappointing 6%-10% 2014 U.S. growth forecast following 18% growth in 2013; the firm still sees Nellix as a long-term growth driver, but there's little to offset near-term U.S. uncertainty with no Nellix data read-outs expected this year and EU constraints not expected to be alleviated until Q4.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs